Potential cost and effectiveness of a nephrologist/nurse-based multifaceted intervention for stage 3 to 4 chronic kidney disease are not known. This study examines the cost-effectiveness of a chronic disease management model for chronic kidney disease.
Cost and cost-effectiveness were prospectively gathered alongside a multicenter trial. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (CanPREVENT) randomized 236 patients to receive usual care (controls) and another 238 patients to multifaceted nurse/nephrologist-supported care that targeted factors associated with development of kidney and cardiovascular disease (intervention). Cost and outcomes over 2 years were examined to determine the incremental cost-effectiveness of the intervention. Base-case analysis included disease-related costs, and sensitivity analysis included all costs.
Consideration of all costs produced statistically significant differences. A lower number of days in hospital explained most of the cost difference. For both base-case and sensitivity analyses with all costs included, the intervention group required fewer resources and had higher quality of life. The direction of the results was unchanged to inclusion of various types of costs, consideration of payer or societal perspective, changes to the discount rate, and levels of GFR.
The nephrologist/nurse-based multifaceted intervention represents good value for money because it reduces costs without reducing quality of life for patients with chronic kidney disease.
Cites: Health Qual Life Outcomes. 2003;1:5414613568
Cites: J Am Soc Nephrol. 2007 Nov;18(11):2953-917942955
Cites: BMJ. 2008 Mar 22;336(7645):645-5118299289
Cites: Am J Med Qual. 2008 May-Jun;23(3):184-9218539979
Cites: Health Technol Assess. 2010 Apr;14(21):1-18420441712
Cites: Clin J Am Soc Nephrol. 2011 Jun;6(6):1241-721617090
The diagnostic accuracy of cystatin C estimated GFR (eGFR) by various cystatin C equations have varied in different studies. We hypothesized that the GFR level of enrolled patients affects the diagnostic accuracy of a cystatin C equation.
We analyzed 240 consecutively enrolled children at a single Canadian center in a prospective and cross-sectional study. Cystatin C was analyzed with nephelometry, and cystatin C eGFR was estimated by the equations validated in children. GFR was measured by technetium-99m-diethylene-triamine penta-acetic acid (??m)Tc DTPA).
We compared various cystatin C equations across GFR strata
It is unclear how to optimally care for chronic kidney disease (CKD). This study compares a new coordinated model to usual care for CKD.
A randomized trial in nephrology clinics and the community included 474 patients with median estimated GFR (eGFR) 42 ml/min per 1.73 m(2) identified by laboratory-based case finding compared care coordinated by a general practitioner (controls) with care by a nurse-coordinated team including a nephrologist (intervention) for a median (interquartile range [IQR]) of 742 days. 32% were diabetic, 60% had cardiovascular disease, and proteinuria was minimal. Guided by protocols, the intervention team targeted risk factors for adverse kidney and cardiovascular outcomes. Serial eGFR and clinical events were tracked.
The average decline in eGFR over 20 months was -1.9 ml/min per 1.73 m(2). eGFR declined by =4 ml/min per 1.73 m(2) within 20 months in 28 (17%) intervention patients versus 23 (13.9%) control patients. Control of BP, LDL, and diabetes were comparable across groups. In the intervention group there was a trend to greater use of renin-angiotensin blockers and more use of statins in those with initial LDL >2.5 mmol/L. Treatment was rarely required for anemia, acidosis, or disordered mineral metabolism. Clinical events occurred in 5.2% per year.
Patients with stage 3/4 CKD identified through community laboratories largely had nonprogressive kidney disease but had cardiovascular risk. Over a median of 24 months, the nurse-coordinated team did not affect rate of GFR decline or control of most risk factors compared with usual care.
Cites: Am J Kidney Dis. 2001 Mar;37(3):484-911228171
Cites: Ann Intern Med. 2001 Apr 17;134(8):629-3611304102
Cites: J Am Soc Nephrol. 2001 Aug;12(8):1713-2011461944
Cites: Ann Med. 2001 Jul;33(5):375-8411491197
Cites: N Engl J Med. 2001 Sep 20;345(12):851-6011565517
Cites: Arch Intern Med. 2004 Mar 22;164(6):659-6315037495
Cites: Am J Kidney Dis. 2004 May;43(5):825-3515112173
Cites: Am J Kidney Dis. 2004 Oct;44(4):706-1415384022
The effect of increased fluid intake on kidney function is unclear. This study evaluates the relationship between urine volume and renal decline over 6 years in a large community-based cohort.
This prospective cohort study was undertaken in Canada from 2002 to 2008. We obtained 24-hour urine samples from adult participants with an estimated GFR (eGFR) =60 ml/min per 1.73 m(2) at study entry. Percentage annual change in eGFR from baseline was categorized as average decline
Cites: J Am Soc Nephrol. 2008 Jan;19(1):1-718032792
Cites: BMJ. 2007 Dec 22;335(7633):1288-918156231
Cites: CMAJ. 2008 Jan 15;178(2):173-518195291
Cites: J Am Soc Nephrol. 2008 Jun;19(6):1076-818337482
Cites: J Am Soc Nephrol. 2008 Jun;19(6):1041-318385417
Cites: Clin J Am Soc Nephrol. 2008 Sep;3(5):1332-818667734
Cites: Lancet. 2008 Sep 6;372(9641):782-418774404
Cites: PLoS One. 2008;3(10):e343118927611
Cites: J Am Soc Nephrol. 2009 Dec;20(12):2617-2419892932
Cites: Nutr Rev. 2010 Aug;68(8):439-5820646222
Cites: J Am Soc Nephrol. 2010 Nov;21(11):1814-620947630